Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

8201	Companies
109005	Keywords
51275	Articles
60079	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

BRIEF

published on 09/03/2024 at 13:35, 1 month 29 days ago

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Clinical Development Fireside Chat Protagonist Therapeutics Rusfertide Global Investment Conference
BRIEF

published on 09/03/2024 at 13:35, 1 month 29 days ago

Protagonist Therapeutics participera à la 26e conférence annuelle mondiale sur l'investissement HC Wainwright 2024

Développement Clinique Discussion Au Coin Du Feu Rusfertide Thérapeutique Protagoniste Conférence Mondiale Sur L'investissement
PRESS RELEASE

published on 09/03/2024 at 13:30, 1 month 29 days ago

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Protagonist Therapeutics, Inc. to participate in H.C. Wainwright 26th Annual Global Investment Conference with CEO Dinesh V. Patel in fireside chat. Focus on Phase 3 clinical development of rusfertide and JNJ-2113

Protagonist Therapeutics Rusfertide H.C. Wainwright Conference JNJ-2113 Phase 3 Clinical Development
BRIEF

published on 07/22/2024 at 13:05, 3 months 12 days ago

Protagonist Therapeutics to Participate in BTIG Virtual Biotechnology Conference 2024

Clinical Development Protagonist Therapeutics Rusfertide BTIG Conference Peptide-based NCEs
BRIEF

published on 07/22/2024 at 13:05, 3 months 12 days ago

Protagonist Therapeutics participera à la conférence virtuelle BTIG sur la biotechnologie 2024

Développement Clinique Rusfertide Thérapeutique Protagoniste Conférence BTIG NCE À Base De Peptides
PRESS RELEASE

published on 07/22/2024 at 13:00, 3 months 12 days ago

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Protagonist Therapeutics, Inc. to participate in BTIG Virtual Biotechnology Conference. Company's lead drug candidate rusfertide in global Phase 3 development for polycythemia vera

Protagonist Therapeutics Rusfertide Polycythemia Vera BTIG Virtual Biotechnology Conference Phase 3 Development
BRIEF

published on 05/14/2024 at 22:10, 5 months 19 days ago

Protagonist Therapeutics to Present New Rusfertide Study Data at EHA Congress 2024

Clinical Study Protagonist Therapeutics Rusfertide Polycythemia Vera EHA Congress 2024
BRIEF

published on 05/14/2024 at 22:10, 5 months 19 days ago

Protagonist Therapeutics présentera de nouvelles données de l'étude Rusfertide au congrès de l'EHA 2024

Étude Clinique Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Congrès EHA 2024
PRESS RELEASE

published on 05/14/2024 at 22:05, 5 months 19 days ago

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Protagonist Therapeutics to present rusfertide Phase 2 REVIVE study data at EHA Congress in Madrid. Study shows absence of QTc prolongation with rusfertide. Details on pipeline drugs and collaborations available on company's website

Clinical Development Collaborations Protagonist Therapeutics Rusfertide EHA Congress

Accesswire

Published on 11/03/2024 at 00:45, 12 hours 27 minutes ago

Holtway Global Hedge Expands into Europe, Providing Exclusive Pre-IPO and IPO Access to Companies Led by Visionary Founders like Elon Musk and Sam Altman
Published on 11/02/2024 at 19:15, 17 hours 57 minutes ago

Hank Payments Announces Closing of Financing and Settlements
Published on 11/02/2024 at 16:10, 21 hours 2 minutes ago

Savencia Cheese USA Announces Voluntary Recall of Select Soft Ripened Cheeses
Published on 11/02/2024 at 14:30, 22 hours 42 minutes ago

Spa Sciences Health Introduces Revolutionary Nasal Irrigation System at CVS
Published on 11/02/2024 at 00:48, 1 day 12 hours ago

OneSoft Solutions Inc. Announces the Completion of Its Acquisition by Irth Solutions LLC, a Blackstone Portfolio Company

View all ACCESSWIRE

EQS Group

Published on 11/01/2024 at 21:31, 1 day 15 hours ago

Original-Research: Telefonica Deutschland Holding AG (von First Berlin Equity Research GmbH): Buy
Published on 11/01/2024 at 18:18, 1 day 18 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/01/2024 at 17:47, 1 day 19 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/01/2024 at 17:10, 1 day 20 hours ago

EQS-Adhoc: fox e-mobility AG: provisional debt restructuring moratorium of Fox Automotive Switzerland AG
Published on 11/01/2024 at 16:00, 1 day 21 hours ago

Total Voting Rights

Les Echos

Published on 10/31/2024 at 20:26, 2 days 16 hours ago

I.CERAM - Résultat du 1er semestre 2024
Published on 10/31/2024 at 18:19, 2 days 18 hours ago

Déclaration hebdomadaire d'opérations effectuées du 28 au 31 octobre 2024
Published on 10/31/2024 at 18:19, 2 days 18 hours ago

Disclosure of transactions in own shares on October 28 to October 31, 2024
Published on 10/31/2024 at 18:00, 2 days 19 hours ago

GUILLEMOT CORPORATION : CHIFFRE D’AFFAIRES TROISIEME TRIMESTRE 2024 : +3%
Published on 10/31/2024 at 18:00, 2 days 19 hours ago

GUILLEMOT CORPORATION: THIRD QUARTER 2024 TURNOVER UP 3%

View all LES ECHOS COMFI WIRE